Protagonist Therapeutics, Inc. (PTGX)
- Previous Close
44.27 - Open
44.44 - Bid 32.41 x 200
- Ask 55.48 x 200
- Day's Range
43.28 - 45.26 - 52 Week Range
27.00 - 60.60 - Volume
288,882 - Avg. Volume
1,281,405 - Market Cap (intraday)
2.691B - Beta (5Y Monthly) 2.64
- PE Ratio (TTM)
55.67 - EPS (TTM)
0.78 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
68.70
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
View More
Performance Overview: PTGX
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
View MoreValuation Measures
Market Cap
2.74B
Enterprise Value
2.18B
Trailing P/E
56.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.83
Price/Book (mrq)
3.98
Enterprise Value/Revenue
10.50
Enterprise Value/EBITDA
72.40
Financial Highlights
Profitability and Income Statement
Profit Margin
27.04%
Return on Assets (ttm)
2.48%
Return on Equity (ttm)
8.99%
Revenue (ttm)
207.8M
Net Income Avi to Common (ttm)
56.19M
Diluted EPS (ttm)
0.78
Balance Sheet and Cash Flow
Total Cash (mrq)
574.36M
Total Debt/Equity (mrq)
1.65%
Levered Free Cash Flow (ttm)
327.76M
Research Analysis: PTGX
View MoreResearch Reports: PTGX
View MoreRating increased to a BUY
PROTAGONIST THERAPEUTICS INC has an Investment Rating of BUY; a target price of $46.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about PTGX?
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $48.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $48.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $48.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $49.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target